# Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF) Inhalation to Improve Host Defense and Pulmonary Barrier Restoration

> **NCT02595060** · PHASE2 · COMPLETED · sponsor: **University of Giessen** · enrollment: 45 (actual)

## Conditions studied

- ARDS

## Interventions

- **DRUG:** inhaled molgramostim (rhGM-CSF)
- **DRUG:** inhaled placebo

## Key facts

- **NCT ID:** NCT02595060
- **Lead sponsor:** University of Giessen
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-06-01
- **Primary completion:** 2021-09-22
- **Final completion:** 2022-07-31
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2023-08-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02595060

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02595060, "Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF) Inhalation to Improve Host Defense and Pulmonary Barrier Restoration". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02595060. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*